 | • レポートコード：GIR-107A12486 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、多発性硬化症治療薬・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。多発性硬化症治療薬・治療の種類別市場規模（インターフェロン、免疫調節剤、免疫抑制剤）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・多発性硬化症治療薬・治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Roche、Biogen、Teva Pharmaceutical、Merck、Novartis、Bayer、Sanofi、Acorda Therapeutics、Questcor Pharmaceuticals、AbbVie、Opexa Therapeutics、Genzyme Corporation ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：インターフェロン、免疫調節剤、免疫抑制剤 ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局、その他 ・多発性硬化症治療薬・治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・多発性硬化症治療薬・治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・多発性硬化症治療薬・治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・多発性硬化症治療薬・治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・多発性硬化症治療薬・治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Multiple Sclerosis Drugs Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Multiple Sclerosis Drugs Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Multiple Sclerosis Drugs Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Multiple Sclerosis Drugs Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Interferon
Immunomodulator
Immunosuppressant
Market segment by Application, can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other
Market segment by players, this report covers
Pfizer
Roche
Biogen
Teva Pharmaceutical
Merck
Novartis
Bayer
Sanofi
Acorda Therapeutics
Questcor Pharmaceuticals
AbbVie
Opexa Therapeutics
Genzyme Corporation
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis Drugs Treatment
1.2 Classification of Multiple Sclerosis Drugs Treatment by Type
1.2.1 Overview: Global Multiple Sclerosis Drugs Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Multiple Sclerosis Drugs Treatment Revenue Market Share by Type in 2020
1.2.3 Interferon
1.2.4 Immunomodulator
1.2.5 Immunosuppressant
1.3 Global Multiple Sclerosis Drugs Treatment Market by Application
1.3.1 Overview: Global Multiple Sclerosis Drugs Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Other
1.4 Global Multiple Sclerosis Drugs Treatment Market Size & Forecast
1.5 Global Multiple Sclerosis Drugs Treatment Market Size and Forecast by Region
1.5.1 Global Multiple Sclerosis Drugs Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Multiple Sclerosis Drugs Treatment Market Size by Region, (2016-2021)
1.5.3 North America Multiple Sclerosis Drugs Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Multiple Sclerosis Drugs Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Multiple Sclerosis Drugs Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Multiple Sclerosis Drugs Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Multiple Sclerosis Drugs Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Multiple Sclerosis Drugs Treatment Market Drivers
1.6.2 Multiple Sclerosis Drugs Treatment Market Restraints
1.6.3 Multiple Sclerosis Drugs Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Multiple Sclerosis Drugs Treatment Product and Solutions
2.1.4 Pfizer Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Multiple Sclerosis Drugs Treatment Product and Solutions
2.2.4 Roche Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Roche Recent Developments and Future Plans
2.3 Biogen
2.3.1 Biogen Details
2.3.2 Biogen Major Business
2.3.3 Biogen Multiple Sclerosis Drugs Treatment Product and Solutions
2.3.4 Biogen Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Biogen Recent Developments and Future Plans
2.4 Teva Pharmaceutical
2.4.1 Teva Pharmaceutical Details
2.4.2 Teva Pharmaceutical Major Business
2.4.3 Teva Pharmaceutical Multiple Sclerosis Drugs Treatment Product and Solutions
2.4.4 Teva Pharmaceutical Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Teva Pharmaceutical Recent Developments and Future Plans
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Multiple Sclerosis Drugs Treatment Product and Solutions
2.5.4 Merck Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Merck Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Multiple Sclerosis Drugs Treatment Product and Solutions
2.6.4 Novartis Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Bayer
2.7.1 Bayer Details
2.7.2 Bayer Major Business
2.7.3 Bayer Multiple Sclerosis Drugs Treatment Product and Solutions
2.7.4 Bayer Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bayer Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Multiple Sclerosis Drugs Treatment Product and Solutions
2.8.4 Sanofi Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Acorda Therapeutics
2.9.1 Acorda Therapeutics Details
2.9.2 Acorda Therapeutics Major Business
2.9.3 Acorda Therapeutics Multiple Sclerosis Drugs Treatment Product and Solutions
2.9.4 Acorda Therapeutics Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Acorda Therapeutics Recent Developments and Future Plans
2.10 Questcor Pharmaceuticals
2.10.1 Questcor Pharmaceuticals Details
2.10.2 Questcor Pharmaceuticals Major Business
2.10.3 Questcor Pharmaceuticals Multiple Sclerosis Drugs Treatment Product and Solutions
2.10.4 Questcor Pharmaceuticals Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Questcor Pharmaceuticals Recent Developments and Future Plans
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Multiple Sclerosis Drugs Treatment Product and Solutions
2.11.4 AbbVie Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 AbbVie Recent Developments and Future Plans
2.12 Opexa Therapeutics
2.12.1 Opexa Therapeutics Details
2.12.2 Opexa Therapeutics Major Business
2.12.3 Opexa Therapeutics Multiple Sclerosis Drugs Treatment Product and Solutions
2.12.4 Opexa Therapeutics Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Opexa Therapeutics Recent Developments and Future Plans
2.13 Genzyme Corporation
2.13.1 Genzyme Corporation Details
2.13.2 Genzyme Corporation Major Business
2.13.3 Genzyme Corporation Multiple Sclerosis Drugs Treatment Product and Solutions
2.13.4 Genzyme Corporation Multiple Sclerosis Drugs Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Genzyme Corporation Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Multiple Sclerosis Drugs Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Multiple Sclerosis Drugs Treatment Players Market Share
3.2.2 Top 10 Multiple Sclerosis Drugs Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Multiple Sclerosis Drugs Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Multiple Sclerosis Drugs Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Multiple Sclerosis Drugs Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Multiple Sclerosis Drugs Treatment Revenue Market Share by Application (2016-2021)
5.2 Multiple Sclerosis Drugs Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2026)
6.2 North America Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2026)
6.3 North America Multiple Sclerosis Drugs Treatment Market Size by Country
6.3.1 North America Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2026)
6.3.2 United States Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2026)
7.2 Europe Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2026)
7.3 Europe Multiple Sclerosis Drugs Treatment Market Size by Country
7.3.1 Europe Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2026)
7.3.2 Germany Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
7.3.3 France Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Multiple Sclerosis Drugs Treatment Market Size by Region
8.3.1 Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Region (2016-2026)
8.3.2 China Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
8.3.5 India Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2026)
9.2 South America Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2026)
9.3 South America Multiple Sclerosis Drugs Treatment Market Size by Country
9.3.1 South America Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Multiple Sclerosis Drugs Treatment Market Size by Country
10.3.1 Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Multiple Sclerosis Drugs Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Multiple Sclerosis Drugs Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Multiple Sclerosis Drugs Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Multiple Sclerosis Drugs Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Multiple Sclerosis Drugs Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Multiple Sclerosis Drugs Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Multiple Sclerosis Drugs Treatment Product and Solutions
Table 9. Pfizer Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Roche Corporate Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Multiple Sclerosis Drugs Treatment Product and Solutions
Table 13. Roche Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Biogen Corporate Information, Head Office, and Major Competitors
Table 15. Biogen Major Business
Table 16. Biogen Multiple Sclerosis Drugs Treatment Product and Solutions
Table 17. Biogen Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Teva Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 19. Teva Pharmaceutical Major Business
Table 20. Teva Pharmaceutical Multiple Sclerosis Drugs Treatment Product and Solutions
Table 21. Teva Pharmaceutical Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Merck Corporate Information, Head Office, and Major Competitors
Table 23. Merck Major Business
Table 24. Merck Multiple Sclerosis Drugs Treatment Product and Solutions
Table 25. Merck Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Multiple Sclerosis Drugs Treatment Product and Solutions
Table 29. Novartis Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bayer Corporate Information, Head Office, and Major Competitors
Table 31. Bayer Major Business
Table 32. Bayer Multiple Sclerosis Drugs Treatment Product and Solutions
Table 33. Bayer Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Multiple Sclerosis Drugs Treatment Product and Solutions
Table 37. Sanofi Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Acorda Therapeutics Corporate Information, Head Office, and Major Competitors
Table 39. Acorda Therapeutics Major Business
Table 40. Acorda Therapeutics Multiple Sclerosis Drugs Treatment Product and Solutions
Table 41. Acorda Therapeutics Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Questcor Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 43. Questcor Pharmaceuticals Major Business
Table 44. Questcor Pharmaceuticals Multiple Sclerosis Drugs Treatment Product and Solutions
Table 45. Questcor Pharmaceuticals Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. AbbVie Corporate Information, Head Office, and Major Competitors
Table 47. AbbVie Major Business
Table 48. AbbVie Multiple Sclerosis Drugs Treatment Product and Solutions
Table 49. AbbVie Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Opexa Therapeutics Corporate Information, Head Office, and Major Competitors
Table 51. Opexa Therapeutics Major Business
Table 52. Opexa Therapeutics Multiple Sclerosis Drugs Treatment Product and Solutions
Table 53. Opexa Therapeutics Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Genzyme Corporation Corporate Information, Head Office, and Major Competitors
Table 55. Genzyme Corporation Major Business
Table 56. Genzyme Corporation Multiple Sclerosis Drugs Treatment Product and Solutions
Table 57. Genzyme Corporation Multiple Sclerosis Drugs Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Global Multiple Sclerosis Drugs Treatment Revenue (USD Million) by Players (2019-2021)
Table 59. Global Multiple Sclerosis Drugs Treatment Revenue Share by Players (2019-2021)
Table 60. Breakdown of Multiple Sclerosis Drugs Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Multiple Sclerosis Drugs Treatment Players Head Office, Products and Services Provided
Table 62. Multiple Sclerosis Drugs Treatment Mergers & Acquisitions in the Past Five Years
Table 63. Multiple Sclerosis Drugs Treatment New Entrants and Expansion Plans
Table 64. Global Multiple Sclerosis Drugs Treatment Revenue (USD Million) by Type (2016-2021)
Table 65. Global Multiple Sclerosis Drugs Treatment Revenue Share by Type (2016-2021)
Table 66. Global Multiple Sclerosis Drugs Treatment Revenue Forecast by Type (2021-2026)
Table 67. Global Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2021)
Table 68. Global Multiple Sclerosis Drugs Treatment Revenue Forecast by Application (2021-2026)
Table 69. North America Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2021) & (USD Million)
Table 70. North America Multiple Sclerosis Drugs Treatment Revenue by Type (2021-2026) & (USD Million)
Table 71. North America Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2021) & (USD Million)
Table 72. North America Multiple Sclerosis Drugs Treatment Revenue by Application (2021-2026) & (USD Million)
Table 73. North America Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2021) & (USD Million)
Table 74. North America Multiple Sclerosis Drugs Treatment Revenue by Country (2021-2026) & (USD Million)
Table 75. Europe Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2021) & (USD Million)
Table 76. Europe Multiple Sclerosis Drugs Treatment Revenue by Type (2021-2026) & (USD Million)
Table 77. Europe Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2021) & (USD Million)
Table 78. Europe Multiple Sclerosis Drugs Treatment Revenue by Application (2021-2026) & (USD Million)
Table 79. Europe Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2021) & (USD Million)
Table 80. Europe Multiple Sclerosis Drugs Treatment Revenue by Country (2021-2026) & (USD Million)
Table 81. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2021) & (USD Million)
Table 82. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2021) & (USD Million)
Table 84. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Region (2016-2021) & (USD Million)
Table 86. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue by Region (2021-2026) & (USD Million)
Table 87. South America Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2021) & (USD Million)
Table 88. South America Multiple Sclerosis Drugs Treatment Revenue by Type (2021-2026) & (USD Million)
Table 89. South America Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2021) & (USD Million)
Table 90. South America Multiple Sclerosis Drugs Treatment Revenue by Application (2021-2026) & (USD Million)
Table 91. South America Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2021) & (USD Million)
Table 92. South America Multiple Sclerosis Drugs Treatment Revenue by Country (2021-2026) & (USD Million)
Table 93. Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Type (2016-2021) & (USD Million)
Table 94. Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Application (2016-2021) & (USD Million)
Table 96. Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Country (2016-2021) & (USD Million)
Table 98. Middle East & Africa Multiple Sclerosis Drugs Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Multiple Sclerosis Drugs Treatment Picture
Figure 2. Global Multiple Sclerosis Drugs Treatment Revenue Market Share by Type in 2020
Figure 3. Interferon
Figure 4. Immunomodulator
Figure 5. Immunosuppressant
Figure 6. Multiple Sclerosis Drugs Treatment Revenue Market Share by Application in 2020
Figure 7. Hospital Pharmacy Picture
Figure 8. Retail Pharmacy Picture
Figure 9. Online Pharmacy Picture
Figure 10. Other Picture
Figure 11. Global Multiple Sclerosis Drugs Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Multiple Sclerosis Drugs Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Multiple Sclerosis Drugs Treatment Revenue Market Share by Region (2016-2026)
Figure 14. Global Multiple Sclerosis Drugs Treatment Revenue Market Share by Region in 2020
Figure 15. North America Multiple Sclerosis Drugs Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Multiple Sclerosis Drugs Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Multiple Sclerosis Drugs Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Multiple Sclerosis Drugs Treatment Market Drivers
Figure 21. Multiple Sclerosis Drugs Treatment Market Restraints
Figure 22. Multiple Sclerosis Drugs Treatment Market Trends
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Roche Recent Developments and Future Plans
Figure 25. Biogen Recent Developments and Future Plans
Figure 26. Teva Pharmaceutical Recent Developments and Future Plans
Figure 27. Merck Recent Developments and Future Plans
Figure 28. Novartis Recent Developments and Future Plans
Figure 29. Bayer Recent Developments and Future Plans
Figure 30. Sanofi Recent Developments and Future Plans
Figure 31. Acorda Therapeutics Recent Developments and Future Plans
Figure 32. Questcor Pharmaceuticals Recent Developments and Future Plans
Figure 33. AbbVie Recent Developments and Future Plans
Figure 34. Opexa Therapeutics Recent Developments and Future Plans
Figure 35. Genzyme Corporation Recent Developments and Future Plans
Figure 36. Global Multiple Sclerosis Drugs Treatment Revenue Share by Players in 2020
Figure 37. Multiple Sclerosis Drugs Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 38. Global Top 3 Players Multiple Sclerosis Drugs Treatment Revenue Market Share in 2020
Figure 39. Global Top 10 Players Multiple Sclerosis Drugs Treatment Revenue Market Share in 2020
Figure 40. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 41. Global Multiple Sclerosis Drugs Treatment Revenue Share by Type in 2020
Figure 42. Global Multiple Sclerosis Drugs Treatment Market Share Forecast by Type (2021-2026)
Figure 43. Global Multiple Sclerosis Drugs Treatment Revenue Share by Application in 2020
Figure 44. Global Multiple Sclerosis Drugs Treatment Market Share Forecast by Application (2021-2026)
Figure 45. North America Multiple Sclerosis Drugs Treatment Sales Market Share by Type (2016-2026)
Figure 46. North America Multiple Sclerosis Drugs Treatment Sales Market Share by Application (2016-2026)
Figure 47. North America Multiple Sclerosis Drugs Treatment Revenue Market Share by Country (2016-2026)
Figure 48. United States Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Canada Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Mexico Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Europe Multiple Sclerosis Drugs Treatment Sales Market Share by Type (2016-2026)
Figure 52. Europe Multiple Sclerosis Drugs Treatment Sales Market Share by Application (2016-2026)
Figure 53. Europe Multiple Sclerosis Drugs Treatment Revenue Market Share by Country (2016-2026)
Figure 54. Germany Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. France Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. United Kingdom Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Russia Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Italy Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Asia-Pacific Multiple Sclerosis Drugs Treatment Sales Market Share by Type (2016-2026)
Figure 60. Asia-Pacific Multiple Sclerosis Drugs Treatment Sales Market Share by Application (2016-2026)
Figure 61. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue Market Share by Region (2016-2026)
Figure 62. China Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Japan Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South Korea Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. India Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Southeast Asia Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Australia Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South America Multiple Sclerosis Drugs Treatment Sales Market Share by Type (2016-2026)
Figure 69. South America Multiple Sclerosis Drugs Treatment Sales Market Share by Application (2016-2026)
Figure 70. South America Multiple Sclerosis Drugs Treatment Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East and Africa Multiple Sclerosis Drugs Treatment Sales Market Share by Type (2016-2026)
Figure 74. Middle East and Africa Multiple Sclerosis Drugs Treatment Sales Market Share by Application (2016-2026)
Figure 75. Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. UAE Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Methodology
Figure 80. Research Process and Data Source
多発性硬化症治療法市場：世界及び中国市場分析・予測（～2024年） Multiple Sclerosis Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Multiple Sclerosis Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Multiple Sclerosis D…- 進行性再発多発性硬化症治療市場：世界及び中国市場分析・予測（～2024年） Progressive Relapsing Multiple Sclerosis Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Progressive Relapsing Multiple Sclerosis Treatment industry with a focus on the Chinese market. The report provides key statist…
- 多発性硬化症治療薬市場：世界及び中国市場分析・予測（～2024年） Multiple Sclerosis Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Multiple Sclerosis Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Multip…
- 筋萎縮性側索硬化症用治療市場：世界及び中国市場分析・予測（～2024年） Amyotrophic Lateral Sclerosis Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Amyotrophic Lateral Sclerosis Treatment industry with a focus on the Chinese market. The report provides key statistics on the market stat…
- 世界の多発性骨髄腫用従来型化学療法薬市場 2021：企業別、地域別、種類・用途別 The Traditional Chemotherapy Drugs for Multiple Myeloma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain…